Literature DB >> 14658193

[Four cases of primary neuroendocrine carcinoma in ear, nose, pharynx and larynx].

Yong Feng1, Gang Xu, Bing Liu, Huaifu Wang, Xueqin Su.   

Abstract

OBJECTIVE: To discuss the clinical pathologic features and therapeutic method of the primary neuroendocrine carcinoma in ear, nose, pharynx, larynx.
METHOD: One case of atypical carcinoid tumor in larynx is treated by epiglottidectomy. One case of atypical carcinoid tumor in rhinopharynx is treated by radiotherapy. One case of typical carcinoid tumor in middle ear is treated by exploratory incision and radical mastoidectomy. One case of small cell neuroendocrine carcinoma in right nasal cavity is treated by resection and radiotherapy. RESULT: The patient of atypical carcinoid tumor in larynx died after 5 years and the patient of atypical carcinoid tumor in rhinopharynx died after 1 year. The patient of typical carcinoid tumor in middle ear was followed-up 3 years and the patient of small cell neuroendocrine carcinoma in right nasal cavity was followed-up 2 years, and the carcinomas didn't recrudesce.
CONCLUSION: The primary neuroendocrine carcinoma in ear, nose, pharynx, larynx is classified in three states: typical carcinoid tumor, atypical carcinoid tumor and small cell neuroendocrine carcinoma. Typical carcinoid tumor is a kind of low malignant tumor and small cell neuroendocrine carcinoma is a kind of high malignant tumor and atypical carcinoid tumor is a kind of medium malignant tumor. The chief therapeutic method of the primary neuroendocrine carcinoma in ear, nose, pharynx, larynx is surgical intervention.

Entities:  

Mesh:

Year:  2003        PMID: 14658193

Source DB:  PubMed          Journal:  Lin Chuang Er Bi Yan Hou Ke Za Zhi


  1 in total

1.  [Poorly differentiated neuroendocrine carcinoma of the larynx. Diagnostic features, treatment strategy, and prognosis].

Authors:  M D Jumah; F Fleiner; S Wendt; M Pavel; M Schwabe; O Göktas
Journal:  HNO       Date:  2009-02       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.